CSL Ltd shares surge 35% on ASX since early June

Australian biotech firm CSL Ltd (ASX:CSL) has seen its share price rise about 35% since the low of $91 on 3 June, reaching $122.89. The rebound follows a nine‑year low in the health‑care index and is driven mainly by sector rotation and valuation re‑assessment rather than new company‑specific news. CSL’s FY26 guidance remains unchanged, with revenue of roughly US$15.2 billion and NPAT of US$3.1 billion, but operational challenges such as US immunoglobulin supply constraints and China albumin pricing pressure persist. Analysts are split, with eight of eighteen rating the stock as a buy and ten as a hold, awaiting the August FY26 results to determine whether the rally is sustainable.

The company operates through CSL Behring, CSL Seqirus and CSL Vifor, and is regarded as a blue‑chip Australian health‑care stock with a long‑track record of dividend payouts. While the share bounce reflects a broader investment shift into undervalued health‑care equities, the upcoming earnings report will test if the valuation uplift is justified by improved division performance and resolution of supply issues.